The Drug Update: Recent drug approvals, summer 2025 edition.

The Nurse practitioner2025PMID: 40722217

View on PubMed DOI: 10.1097/01.NPR.0000000000000344

Plain Language Summary

This drug update highlights recent FDA approvals relevant to primary care including tirzepatide and related medications. The practical overview helps clinicians stay current with the rapidly evolving pharmacotherapy landscape.

Abstract

In the final half of 2024, the US FDA approved several new drugs that have relevance for those practicing in primary care. This article highlights the following new medications: donanemab-azbt (Kisunla), nalmefene injection (Zurnai), epinephrine nasal spray (neffy), palopegteriparatide (Yorvipath), xanomeline and trospium chloride (Cobenfy), and sulopenem etzadroxil/probenecid (Orlynvah). Additionally, this article highlights the recent approval of obstructive sleep apnea as a new indication for tirzepatide (Zepbound) and chronic obstructive pulmonary disease as a new indication for dupilumab (Dupixent).

Authors

Marino, Adriane B; Drake, Evan S; Theroux, Jenna D; Osteen, Ryan; Sarpong, Rebecca; Hughes, Ashlyn; Plummer, Janna

Keywords

Alzheimer's diseaseFDAFDA approvalacute uncomplicated cystitisallergic reactionanaphylaxischronic obstructive pulmonary diseasehypoparathyroidismnovel drugsobstructive sleep apneaopioid overdoseprimary careschizophrenia